ArticleCureus2025
Current Epidemiological and Clinical Features of Sarcoidosis in Japan: A Nationwide Claims Data Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From guidelines to reality: how do physicians really manage sarcoidosis?BMC pulmonary medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundComprehensive epidemiological and geoepidemiological data on sarcoidosis in Japan, particularly including mild cases, remains limited. This study investigated the prevalence, cumulative incidence, and clinical characteristics of sarcoidosis using large-scale claims data.
methodsThis retrospective study analyzed data from the Deidentified Scrubbed Claims Healthcare Database (DeSC), covering approximately 20 million individuals in Japan. We investigated patients diagnosed with sarcoidosis between April 2014 and October 2023. The prevalence and cumulative incidence were calculated for fiscal year 2021 (FY2021), and patient characteristics, including comorbidities and treatments, were analyzed.
resultsIn FY2021, the estimated prevalence and cumulative incidence of sarcoidosis were 73 and 9.0 per 100,000, respectively. Among 10,910 cases analyzed for clinical characteristics, 68.8% were female individuals, with a mean age of 69.7 years for female individuals and 62.6 years for male individuals. No clear regional differences were observed in prevalence or cumulative incidence (not tested). Oral corticosteroids were prescribed to 25.2% of patients, with a median annual dose of 1,645 mg. Other systemic treatments were prescribed to <3% of patients. The common comorbidities included type 2 diabetes mellitus (21.6-50.0%), sleep disorders (25.1-36.0%), and fractures (8.2%). Sarcoidosis was also associated with other autoimmune diseases, including rheumatoid arthritis, Sjögren syndrome, and autoimmune thyroiditis.
conclusionThe results of this study provide new insights into sarcoidosis epidemiology and clinical characteristics in Japan, including treatment patterns and comorbidities. These findings suggest potential shared immunological mechanisms among various autoimmune diseases and highlight the need for comprehensive management approaches that consider both disease-specific and treatment-related complications. This article was previously presented as a meeting abstract at the 65th Annual Meeting of The Japan Respiratory Society on April 12, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.